Transcriptic Raises $13.4m to Fuel Further Expansion

New Capabilities Will Significantly Increase Impact

MENLO PARK, Calif., Nov. 17, 2016 – Transcriptic Inc., a robotic cloud laboratory for life sciences, today announced the closing of a $13.4 million Series A-1 investment. The new funding was led by Data Collective, along with new investors Digital Science and WuXi AppTec. Existing investors, including AME Cloud Ventures, and others also contributed to the round.

Transcriptic will utilize the new capital to drive the company’s product, team and expansion plans. Since the company launched in 2012, the company has executed experiments for individual researchers, institutions and large pharmaceutical businesses. The new funds will allow the company to grow its team to accommodate further growth, extend the capabilities of its innovative platform, and deliver on its vision of using its automated platform to dramatically increase research productivity.

In today’s increasingly digital research environment, where consistent data is essential and reproducibility of results a necessity, Transcriptic is redefining how research is delivered. The company, which developed the open source Autoprotocol language for codifying lab protocols, helps researchers take their research to an automated, highly-scalable and safe environment in which machine learning techniques can be used to to speed up discovery.

"Since we founded Transcriptic in 2012, we have seen a significant change in how the industry thinks about lab work," said Max Hodak, CEO of Transcriptic. “The Transcriptic platform has freed researchers from many hours of painstaking, error-prone work and enabled them to focus where their time is most valuable. Our goal is to make life science research cheaper, faster, and more accessible, and today’s investment will enable us to deliver further innovations to make that a reality.”

“At Data Collective (DCVC), we are investing at the intersection of AI, robotics, and hyper-scale data and compute to transform global industries,” said Matt Ocko, Managing Partner.  “DCVC has doubled down on Transcriptic because they are uniting these technologies to free life sciences researchers from the heavy tax of assembly-line lab processes, enabling them to accelerate life-saving breakthroughs.”

“Our mission at Digital Science is to bring innovative tools to researchers that allow them to spend more time where they add most value, so Transcriptic is a perfect fit for us,” said Daniel Hook, CEO of Digital Science. “In addition to sharing very similar goals, there is also significant potential for cooperation and integration with other products in our portfolio of companies, including Tetrascience, Labguru, BioRAFT and Figshare.”

 

About Transcriptic Inc.

Transcriptic is the robotic cloud laboratory for life sciences. Transcriptic’s revolutionary, automated cellular and molecular biology platform enables scalable life science research with flexibility and precision. The convenient and simple web interface allows biologists to control their science and generate data from virtually anywhere in the world. Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible. More information on Transcriptic can be found at www.Transcriptic.com.

 

Media Contact:
Taylor Murphy
Chief of Staff, Transcriptic
[email protected]

 

Study Shows How Transcriptic’s Robotic Cloud Laboratory Removes Bottlenecks from Biology Experiments and Generates Reproducible, Publishable Data

 Results Published in PLOS ONE Report Largest Enzyme Mutant Data Set Generated to Date

MENLO PARK, Calif., Feb. 16, 2016 -- Transcriptic, Inc., a robotic cloud laboratory for life sciences, today announced a peer-reviewed study has been published in PLOS ONE that provides an example of how researchers are successfully using Transcriptic Workcells to automate and streamline their biology research.

In the study, researchers at University of California, Davis used the Transcriptic Robotic Cloud Laboratory to improve a critical step in the workflow of computational enzyme design – site-directed mutagenesis, a basic but time-consuming process that is prone to errors. Results from the study show how Transcriptic Workcells automate mutagenesis at a scale and speed necessary for generating large-scale datasets.

“To the best of our knowledge, the research community has not previously produced, purified, and measured the kinetic constants of more than 32 mutants in a uniform manner,” said Justin Siegel, Ph.D., Assistant Professor and Head of the Siegel Lab at the UC Davis Department of Chemistry. “As a result of the team’s work, and the support we received from Transcriptic, we have now generated an order of magnitude more data than any previous effort, making this the largest dataset of its kind.”

“By offering the Siegel Lab a virtual infrastructure to run the mutagenesis process, we streamlined their protocol, enabling automated high-throughput and robust mutagenesis via the cloud,” said Max Hodak, CEO of Transcriptic. “This newly generated dataset is not only an important step forward in enzyme characterization, but the published study is a seminal milestone for Transcriptic. To our knowledge, it is the first published paper that demonstrates how a cloud-based laboratory can remove unnecessary bottlenecks from research experiments and generate reproducible and publishable data.”  

Alex Carlin, lead scientist of the study and graduate student in the Siegel Lab commented: “From an academic standpoint, it’s important that we share our protocols with the scientific community. The mutagenesis protocol we used is available to any Transcriptic customer and will be invaluable for the development of computational enzyme engineering algorithms that provide insight into the physical basis of enzyme sequence-structure-function relationships.”

“We are looking forward to working with Transcriptic to help us scale from 100 mutants to 1000 mutants,” Mr. Carlin added.

Paper Cited:

Carlin, D, et al. Kinetic Characterization of 100 Glycoside Hydrolase Mutants Enables the Discovery of Structural Features Correlated with Kinetic Constants. PLOS ONE. 10.1371/journal.pone.0147596. January 27, 2016.

About Transcriptic Inc.

Transcriptic is the robotic cloud laboratory for life sciences. Transcriptic’s revolutionary, automated cellular and molecular biology platform enables scalable life science research with flexibility and precision. The convenient and simple web interface allows biologists to control their science and generate data from virtually anywhere in the world. Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible. More information on Transcriptic can be found at www.Transcriptic.com.

 

Media Contact:
Maurissa Messier of Bioscribe Inc.
[email protected]
760-659-6700

 

 

 

 

Desktop Genetics Partners with Transcriptic Inc

LONDON, UK (November 5, 2015) — Desktop Genetics Ltd (“DTG” or “the Company”) a software company revolutionizing the way biologists use CRISPR/Cas9 gene editing technology, announced today that it has signed a partnership agreement with Transcriptic Inc, (Transcriptic), a California based robotic cloud laboratory for Life Sciences.

The partnership, announced at the SynBioBeta conference, will combine DTG’s CRISPR/Cas9 design software with Transcriptic’s services for cloud-based, high throughput cloning of CRISPR constructs, which will enable to companies to provide customers with seamless “CRISPR gene editing on-demand”. From today, researchers in industry and academia will be able to benefit from access to the integrated offering, which aims to eliminate time-intensive manual steps involved in the gene editing process to reduce the complexity, costs and time required to modify any gene in any organism or cell line.

Under the terms of the agreement, DTG will provide proprietary, high-performance CRISPR library design algorithms from the DeskGen gene-editing platform, while Transcriptic will conduct the automated, high-throughput assembly of the CRISPR libraries using their self-contained robotic molecular biology labs, known as Workcells. Through a simple web browser interface, customers will have full input on experimental design parameters and will effectively eliminate several time-intensive manual steps involved in the gene editing process.

Riley Doyle, CEO of Desktop Genetics, commented:

“Most labs are limited to an output of around eight cell lines per year. This partnership will allow our customers to scale their research by orders of magnitude by addressing several key bottlenecks, namely the enormous up-front capital expenditure required to set up high-throughput genome editing facilities, and an onerous CRISPR design process.  I am also tremendously excited about optimizing our CRISPR/Cas9 design rules by generating the extensive and sufficiently consistent datasets required to employ our machine learning approaches.”


Yvonne Linney, COO of Transcriptic, commented:

“Combining our workflows with DTG will offer the fastest method of progressing from sequence design to high throughput molecular biology. By removing human error from tedious cloning steps at the bench, researchers will benefit from unmatched reproducibility which in turn will increase the efficiency in downstream cellular analysis.”

 

Notes to Editors

Media Contacts:
Lorna Cuddon, Zyme Communications
Tel: +44 (0)7811 996 942
E-Mail: [email protected]

At Desktop Genetics:
Victor B Dillard, COO and Founder
E-Mail: [email protected]

At Transcriptic;
Yvonne Linney, COO of Transcriptic Inc
Email:
[email protected]

About Desktop Genetics, Ltd. www.deskgen.com

Desktop Genetics develops technologies at the intersection of biotechnology, software and laboratory automation. The company is staffed by molecular biologists and computer scientists and has developed the DeskGen platform, an intuitive and powerful system that supports the optimal design, construction, management, and purchase of the DNA, reagents and services important in gene editing and molecular biology.

Through its platform, the company is enabling “literal Desktop Genetics”, a process that researchers can use to design CRISPR gene editing experiments, purchase reagents and find commercial entities to execute those experiments - and obtain results - without them having their own specialist laboratories.

The Company is currently working with several recognized leaders in the gene editing field, including Editas Medicine, Horizon Discovery and enEvolv.

About Transcriptic Inc www.transcriptic.com

Transcriptic is the robotic cloud laboratory for life sciences. Transcriptic’s revolutionary, automated cellular and molecular biology platform enables scalable life science research with flexibility and precision. The convenient and simple web interface allows biologists to control their science and generate data from virtually anywhere in the world. Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible.

Transcriptic’s investors include IA Ventures, Google Ventures, Data Collective, AME Cloud Ventures, Founders Fund, Naval Ravikant, and Mark Cuban, among others.

IndieBio Secures Partnership with Transcriptic to Accelerate Biology

SAN FRANCISCO (May 11, 2015) — IndieBio, the leading global biotech accelerator, today announced an exclusive partnership with the robotic cloud laboratory platform Transcriptic for up to $60,000 per year in free services for the companies they fund and accelerate.

The Transcriptic credits will be divided evenly among the companies in each new class at IndieBio. IndieBio currently has 12 companies in their inaugural San Francisco based class and plans on admitting approximately 30 per year (15 per cycle). This partnership is the first in a series of announcements by IndieBio as they prepare to open applications for their next application cycle.

We are incredibly excited to be announcing this partnership with Transcriptic and working to accelerate biology together. From the beginning, our aim in founding IndieBio has been to give scientists and entrepreneurs a new, lower cost path to innovation in Independent Biology.

We evolve, like the companies we fund, so expect to hear some very big, additional news from us next week on this continued acceleration.

Ryan Bethencourt, Program Director, IndieBio

We believe cloud science will enable a better future and we’re excited to partner Transcriptic to help enable that future.

Arvind Gupta, Partner SOSventures and Founder IndieBio

Transcriptic, a venture-backed on-demand science company that enables researchers to run their experiments remotely through a web based interface, has democratized access to biotech automation. Transcriptic can execute a wide range of common molecular biology workflows with high repeatability and low cost. From their 10,000 sq. ft. Menlo Park facility, Transcriptic services clients spanning the globe with always-on infrastructure.

The platform enables scientists to remove the intense manual labor that encompasses 70% of research and development time. While useful for all, this is especially valuable for small companies who need reliable data and longer capital runways.

Max Hodak, CEO, Transcriptic

IndieBio views biology as technology and invites applicants from across the life sciences from food, biomaterials to new therapeutics, melding biology, software and robotics to apply for the spring and winter batches. IndieBio funds and accelerates company’s developing solutions with biology to some of the world’s most intractable problems with the broad vision of moving our world from one of scarcity to one of abundance.

Transcriptic is pivotal to accelerating our r&d program. they allow us to conduct meaningful and reproducible experiments without having to incur the expensive capital cost of buying additional scientific equipment or hiring additional staff to conduct these crucial experiments.

Leo Wan, CSO & Co-Founder, Ranomics (IB1)

About Transcriptic

Transcriptic is a revolutionary platform that enables life science research at lower cost, greater precision, and with more seamless collaboration than ever before. Transcriptic designs, builds and operates a state-of-the-art, on-demand research infrastructure as a service for researchers all over the world. Like the earlier "fabless semiconductor" revolution, Transcriptic enables a whole new class of "labless biotech" companies built around faster, more reliable, more repeatable processes with vastly lower capital costs than previously possible, freeing researchers to focus on the creative aspects of their science. Transcriptic’s team of highly qualified Ph.D. scientists and engineers provides valuable design input and debugs protocols. Investors in Transcriptic include IA Ventures, Google Ventures, Data Collective, AME Cloud Ventures, Founders Fund, Naval Ravikant, and Mark Cuban, among others.

Transcriptic Expands Cloud-based Automated Laboratory, Creates New Space for Proprietary Customizable Work Cells

  • New Menlo Park Location Has 10,000 Square Feet, Nearly Five Times the Space of Transcriptic’s Original Lab
  • Transcriptic’s Automated Work Cells Contain Custom-built Hardware to Meet the Individual Needs of Each Research Project

SAN FRANCISCO (September 29, 2014) — Transcriptic, a cloud-based research services provider, today announced that to better meet growing demand for its unique on-demand infrastructure that lowers costs while increasing the reliability of life science research, it has moved its automated lab and customized work cells to a new 10,000 square foot facility in Menlo Park, California.

Transcriptic has reimagined life science lab work by offering a "virtual infrastructure" that gives researchers the ability to design biological experiments via an online interface and advanced APIs (application programming interface) while outsourcing the manual labor component to Transcriptic’s automated lab. This eliminates the need for researchers to be present in the lab during the lab work phase of research, and experiments can run around the clock. Transcriptic’s platform allows researchers to run many projects in parallel and remotely monitor progress and view quality control data at any time via Transcriptic’s online interface.

Combining Transcriptic’s programmable system for defining and executing experimental protocols with its state-of-the-art automated lab has proven to create a 10-fold productivity advantage for researchers working on molecular and cell biology. The new lab facility provides nearly five times the space of Transcriptic’s original lab, allowing for more of the company’s proprietary customizable robotic work cells.

"Lab equipment is expensive and running experiments can be a monotonous and time-consuming experience," said Max Hodak, CEO of Transcriptic. "We’ve designed Transcriptic to remove as many as these limitations and roadblocks as possible so researchers can refocus their efforts on more pure scientific discovery. Now, with all this new lab space we can expand our infrastructure, which will allow us to serve additional clients and give them ever greater flexibility and scalability in their research."

Each work cell is an automated molecular biology lab that contains all the lab equipment needed to run a wide range of experiments. To provide greater experiment flexibility, Transcriptic custom builds hardware for the work cells, including automated freezers, incubators, robotic arms and microplate sealers. These machines are slotted into the work cell in a modular fashion, which allows for easy reconfiguration to meet the individual needs of each research project. The robotic arm is programed to move microplates between the various pieces of equipment, meaning all experimentation can be performed completely autonomously in the work cell.

"Not only does our system provide researchers access to the equipment they need to run experiments remotely, but by building our own hardware to fit the specific needs of our customer we’re able to achieve significantly greater cost efficiency and improve on limitations found in off-the-shelf hardware," added Hodak.

In addition to access to a wide array of state-of-the-art lab equipment and the most advanced APIs for customizing experimentation protocols, Transcriptic also offers unparalleled collaboration with a team of highly qualified Ph.D. scientists and engineers who provide valuable support at every step of the process.

For more information on Transcriptic’s services, visit www.transcriptic.com.

About Transcriptic

Transcriptic is a revolutionary platform that enables life science research at lower cost, greater precision, and with more seamless collaboration than ever before. Transcriptic designs, builds and operates a state-of-the-art, on-demand research infrastructure as a service for researchers all over the world. Like the earlier "fabless semiconductor" revolution, Transcriptic enables a whole new class of "labless biotech" companies built around faster, more reliable, more repeatable processes with vastly lower capital costs than previously possible, freeing researchers to focus on the creative aspects of their science. Transcriptic’s team of highly qualified Ph.D. scientists and engineers provides valuable design input and debugs protocols. Investors in Transcriptic include IA Ventures, Google Ventures, Data Collective, AME Cloud Ventures, Founders Fund, Naval Ravikant, and Mark Cuban, among others.

Transcriptic Launches Science-as-a-Service Platform to Accelerate Biological Research

  • New APIs Offer More Experimental Control, Allowing Scientists to Design Custom Biological Research Protocols and Execute Them Remotely on Demand
  • Transcriptic’s Approach Fuses Personal Expertise with Controlled Automation
  • Company Investors Include IA Ventures, Google Ventures, Data Collective, AME Cloud Ventures, Founders Fund, Naval Ravikant, and Mark Cuban, Among Others

SAN FRANCISCO (July 15, 2014) — Transcriptic, a cloud-based research services provider, today announced the launch of Transcriptic Platform, a programmable system for defining and executing experimental protocols that have proven to create a 10-fold productivity advantage for researchers working on molecular and cell biology.

Transcriptic Platform reimagines life science lab work by combining precise, machine-readable protocol contracts and a remote on-demand infrastructure accessible via a newly released API (application programming interface). This approach allows users to maintain full experimental control while remotely executing the protocols using Transcriptic’s automated lab infrastructure, effectively eliminating the time-intensive manual labor component of laboratory research.

"By its very nature, life science research is a slow, expensive and labor-intensive endeavor. Transcriptic’s mission is to provide the infrastructure necessary to lower costs, improve reproducibility, and allow researchers to do the projects that right now they can only wish they could run," said Max Hodak, Transcriptic’s CEO. "Scientists no longer have to purchase expensive equipment or be chained to the bench to run their experiments. Transcriptic frees up researchers to focus on the creative aspects of scientific discovery that drive important medical advances and make critical discoveries possible."

Unlike traditional lab services offered by contract research organizations (CROs), Transcriptic Platform allows for direct control of the experimental protocol by the customer, enabling far more sophisticated and dynamic applications. Transcriptic’s Common Lab Environment (TCLE) uniquely combines proven hardware, innovative new software, and the human element.

Not only do users have access to a wide array of state-of-the-art lab equipment and the most advanced APIs for customizing experimentation protocols, but Transcriptic also offers unparalleled collaboration with a team of highly qualified Ph.D. scientists and engineers who provide valuable support at every step of the process. The platform is also scalable to meet the needs of numerous clients at one time. Researchers can run many projects in parallel and can remotely monitor progress and view quality control data via Transcriptic’s online interface.

In addition to the platform, Transcriptic also announced its Research Partnership Program, which allows customers with projects that produce a high volume of output to have the option of performing a low-cost test run to ensure reliable results, and then receive a deep discount on scaling up their validated protocol.

Research in labs at several higher education institutions – including Stanford, Harvard, Cal Tech, and UC Davis, among others – have used Transcriptic to streamline their research. The UC Davis Genome Center has used Transcriptic to outsource the creation and processing of samples for projects ranging from bio fuels to cancer therapies to specialty chemicals, ultimately eliminating a time consuming procedural step.

"The building phase is a critical component to research, but can be extremely mundane, repetitive, and mindless," said Justin Siegel, assistant professor of Chemistry, Biochemistry, and Molecular Medicine at the UC Davis Genome Center. "Using Transcriptic has fundamentally changed the way we approach research, because we can rely on them to do that leg work, freeing up our students to spend more time on the creative aspects of research like design and building. These new APIs have simplified the process even more, which will ultimately help us produce even more efficient and reliable output."

Transcriptic’s approach to lab work has resonated with investors, and the company has received $6 million in total funding from IA Ventures, Google Ventures, Data Collective, AME Cloud Ventures, Founders Fund, Naval Ravikant, Mark Cuban, among others.

"Some of the smartest people I know spend a majority of their time on mundane tasks like manually moving around small volumes of liquid, labeling samples, culturing cells, etc. This inefficient approach is a real speed bump to innovation," said Blake Byers, general partner at Google Ventures. "Over the last decade, we’ve seen firsthand the unprecedented advances in computer engineering enabled by abstracted programming tools, which empower innovators to focus on their core product, rather than recreating all the commoditized guts. Transcriptic is ushering in a parallel revolution in biological research by building out an experimental toolset that mirrors the abstracted nature web development and computer engineering. We are excited to partner with Transcriptic and accelerate the pace of biological science development."

TeselaGen and Transcriptic to Partner on Biological Computer Aided Design and Manufacturing Integration

SAN FRANCISCO (November 15, 2013) — TeselaGen (http://www.teselagen.com) and Transcriptic (http://www.transcriptic.com) have announced a strategic partnership to advance the integration of computer-aided design with computer-aided manufacturing for biology. The two companies will work together to build a seamless experience for scientists to manage, design, assemble, and test biomolecules in an easy and cost-effective way. Initially, the companies will focus on automated assembly of complex DNA and protein expression libraries of importance to their customers. This will allow scientists to engineer cells to more efficiently carry out desirable operations, such as producing medications and chemicals.

TeselaGen will offer its state of the art computer aided design and manufacturing platform for rapid prototyping of biomolecules. User requests are turned into cost-optimized protocols automatically, which can then be delivered to vendors who can fulfill those requests. Transcriptic will open its new groundbreaking API for laboratory services to TeselaGen so that automatically generated protocols can be transmitted directly to Transcriptic for execution. The integration of TeselaGen’s cloud based BioCAD platform with Transcriptic’s BioCAM platform will offer clients a comprehensive design, build and test experience, with data flowing freely between the two platforms so that both the design and manufacturing sides of the process can learn from test data and improve processes and designs. For example, data from Transcriptic’s QC assays can feed back to TeselaGen’s design tools where the request was generated and where the data is most useful and relevant to customers.

"Transcriptic’s vision of creating an API for the lab dovetails perfectly with what are trying to accomplish at TeselaGen. We are very focused on improving our customers experience with getting molecules built and tested quickly,” said Michael Fero, CEO, TeselaGen. "Among our clients are many small startups and individual researchers who are already benefiting from being able to use our tools instead of having to build expensive in-house capabilities. Now, we find that much bigger customers are also looking to exploit a more cloud-based model for biomolecule R&D. We believe that in the future we will see more customers moving not only their IT infrastructure to the cloud, but also execution of complex R&D workflows as well. The current practice of using form-based input disconnected from design tools is archaic. We feel our users should have the same sort of seamless design/build/test experience as our colleagues in the electronic design industry. Transcriptic’s vision of creating an efficient service model for common laboratory processes fits well with our vision of being able to do entire experiments in the cloud… with complex requests going out, and comprehensive results coming back, as quickly as physical possible with minimum human intervention."

"TeselaGen’s experience and capabilities in automated biomolecule design make them a good partner for building on the advanced execution platform that we’ve built," said Max Hodak, CEO, Transcriptic. "The markets TeselaGen serves are same ones that we do. The problems we solve are complementary, and by partnering with TeselaGen we can provide our customers with a more complete design to delivery experience. One of our imperatives this year is to find good strategic partners that can complement our business model and begin feeding our request fulfillment pipeline. TeselaGen is a great partner because they understand what we are trying to accomplish for our customers and can work closely with us to give us the information we need in a seamless fashion."

About Transcriptic

Transcriptic is a privately held company based in Menlo Park, CA. The company owns and operates a robotic laboratory infrastructure as a service so that scientists can spend less time at the bench and more time on the creative aspects of their research. Transcriptic Platform is the world’s first Application Programming Interface for biology, with capabilities ranging from DNA synthesis to running complex assays. Transcriptic’s customers include labs at Stanford, Caltech, UC San Diego, the University of Chicago, and several unannounced companies in industry. http://www.transcriptic.com

About TeselaGen

TeselaGen is a synthetic biology platform that enables the development of viral constructs, biologic medicines, and sustainably sourced chemicals. TeselaGen is privately held and is based in San Francisco, CA. Recently founded by three former Stanford fellows and housed at the QB3 incubator at UCSF, the company has received early recognition in the form of two US National Science Foundation grants, a US Department of Energy grant and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution® technology for efficient rapid prototyping of recombinant molecules. The company's customers that are helping validate its approach include Amgen (USA), Genomatica (USA), and Redbiotec (Switzerland). http://www.teselagen.com

Transcriptic Adopts SnapGene Software

CHICAGO, IL (September 20, 2013) — GSL Biotech announced today that Transcriptic, a Silicon Valley company, has adopted SnapGene both for its in-house team of scientists and for use by its customers. Transcriptic is now providing customers with short-term access to SnapGene for use during the ordering process.

Max Hodak, President of Transcriptic, said, "We wanted a simple way for our customers to design and simulate In-Fusion cloning and Gibson Assembly with absolute certainty regarding the product they would receive from us. We found our solution in SnapGene." Cornelia Scheitz, Transcriptic Staff Scientist remarked, "We are getting great feedback on SnapGene from our customers, and the longer I use it for my own work, the more I love it."

Aline Glick, VP of Product Management for GSL Biotech said, "We have similar goals to Transcriptic, in that we are both invested in helping science move faster. I am thrilled that we have been able to work with Transcriptic to provide a time-reducing solution for them and their customers." Video demos of SnapGene’s In-Fusion cloning and Gibson Assembly simulation abilities are available at the company website.

About GSL Biotech

GSL Biotech was founded by scientists and software designers to meet the everyday needs of molecular biologists. GSL's SnapGene software (snapgene.com) provides a simple yet powerful way for researchers to plan, visualize, document, and share their everyday molecular biology procedures. Free trials of the software are available from the SnapGene website.

In addition to the fully functional paid product, GSL Biotech offers the free SnapGene Viewer, which includes the key visualization tools of SnapGene, and allows researchers to make DNA maps and design primers. The annotated sequence files can be shared with colleagues or customers.

About Transcriptic

Flawless experiments, every time. Transcriptic is an on-demand life science research platform. Use state-of-the-art equipment without any upfront costs or the need to synchronously run protocols by hand. Simply configure your protocol online, run it remotely in Transcriptic automated laboratories, and monitor the results in real-time. Transcriptic is focused on dramatically improving throughput, accessibility, and reproducibility of basic research, to support a new generation of lighter, more efficient research groups and companies.

Transcriptic Raises $1.2 Million from Venture Capital Firms and SecondMarket

SAN FRANCISCO (December 12, 2012) — Transcriptic, a start-up biotech company that is developing next-generation lab automation and virtualization technology, today announced $1.2 million in seed funding from a broad group of investors including Google Ventures and FF Angel, and private investors Mark Cuban and Naval Ravikant. In addition, more than 60 individual accredited investors participated through a partnership between AngelList and SecondMarket making Transcriptic the first company to raise a significant equity round online.

"To our knowledge, this is the most widely subscribed seed round to date with over 70 investors participating,” said Transcriptic founder Max Hodak. “We're already seeing the benefits of having such a broad base of support helping us including several top-tier venture capital groups and outstanding angel investors."

Investors participating through the AngelList - SecondMarket partnership could invest as little as $1,000 through their SecondMarket brokerage accounts. The online investment option was added late in Transcriptic’s fundraising process and quickly gathered interest for more than $500,000, despite being shared with only a small fraction of AngelList and SecondMarket’s investor bases. The company ultimately accepted $150,000 through the SecondMarket fund.

"Max has a novel and compelling concept and is backed by some of tech's best-known investors. I was excited to share the deal on AngelList,” said Naval Ravikant, AngelList’s founder.

Transcriptic is developing tools that re-imagine the life science research lab. "Biology research will shift from requiring a million dollar lab and painstaking hours working by hand to something done through a laptop from Starbucks," Mr. Hodak explained. "Our technology represents a very sharp break from tradition in this industry."

“Transcriptic is creating technologies that have the potential to impact biology in the same way that cloud computing has impacted information technology,” said Wesley Chan, general partner at Google Ventures. “We are impressed with Max’s vision, team knowledge, and expertise and look forward to working with them as they scale their operations.”

Transcriptic's first product, a molecular cloning service, has served as a stepping stone for the underlying platform that was developed and tested with live customers over the last few months. The company is now accepting new customers for that product on a limited basis before it releases a broader service in 2013.

About Transcriptic

Transcriptic (https://www.transcriptic.com) was founded to make basic research in the life sciences faster, cheaper, and more repeatable. Transcriptic develops and operates automation technology for running experimental protocols without any of the costs traditionally associated with running a professional research lab. Transcriptic’s first product is an on-demand molecular cloning service designed to take the frustration out of plasmid creation.

About Google Ventures

Google Ventures provides seed, venture and growth stage funding to the most innovative and promising entrepreneurs across a variety of stages. Founded in 2009, Google Ventures helps its entrepreneurs succeed by providing access to uniquely hands-on and dedicated resources such as its Design Studio, Marketing, Recruiting, and Engineering Teams, and Startup Lab. The Google Ventures team has extensive entrepreneurial experience, deep technical knowledge and expertise in building high growth, scalable products and companies. Among its 100+ investments are Nest, Kabam, HomeAway, DocuSign, ngmoco, and WhaleShark Media. Google Ventures is headquartered in Mountain View, Calif. with offices in Cambridge, Mass., Seattle, Wash. and New York, N.Y. For more information, please visit www.googleventures.com.

About FF Angel

FF Angel is Founders Fund’s seed-stage investing arm. Founders Fund, whose partners and funds were the first outside and institutional investors in companies including Facebook and SpaceX, is a San Francisco based venture capital firm that invests in transformational technology businesses. The firm is distinguished by the entrepreneurial experience of its investment partners: Peter Thiel, Ken Howery, Luke Nosek, Brian Singerman and Sean Parker – successful founders of companies worth $1 billion or more – and by its novel pursuit of investments in companies that seek very large markets, usually through significant technological breakthroughs.

About AngelList

AngelList (http://angel.co) is the world's most active online platform for fundraising and recruiting startups. Nearly 2,000 startups from all over the world have met over 5,000 sophisticated investors via AngelList and have then gone on to raise over $1.3B in subsequent funding. AngelList has also facilitated over 20,000 introductions between developers, designers, and recruiting technology companies.

About SecondMarket

SecondMarket's goal is to revolutionize the financial markets by creating a trusted global platform that more efficiently allocates capital through technology-enabled solutions. Since its founding in 2004, the company has developed the largest centralized community of qualified institutional and individual investors, and facilitated billions of dollars of transactions in a variety of unique asset classes. SecondMarket also provides customized capital solutions and innovative tools for fund managers and private companies, enabling them to engage with their stakeholders and the SecondMarket investor community. SecondMarket is backed by FirstMark Capital, The Social+Capital Partnership, Li Ka-shing Foundation, Temasek Holdings, New Enterprise Associates (NEA) and Silicon Valley Bank. SecondMarket is a registered broker-dealer and member of FINRA, MSRB and SIPC and a registered alternative trading system (ATS) for private company stock. For more information, please visit SecondMarket.com.